We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics
Read MoreHide Full Article
The upcoming report from Medtronic (MDT - Free Report) is expected to reveal quarterly earnings of $1.39 per share, indicating an increase of 10.3% compared to the year-ago period. Analysts forecast revenues of $9.47 billion, representing an increase of 10.4% year over year.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Medtronic metrics that are routinely monitored and predicted by Wall Street analysts.
The average prediction of analysts places 'Net Sales- World Wide Revenue- Other' at $19.75 million. The estimate indicates a change of -72.6% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- World Wide Revenue- Neuroscience' will reach $2.67 billion. The estimate suggests a change of +10.7% year over year.
The combined assessment of analysts suggests that 'Net Sales- World Wide Revenue- Cardiovascular' will likely reach $3.78 billion. The estimate suggests a change of +15.2% year over year.
Analysts forecast 'Net Sales- World Wide Revenue- Medical Surgical' to reach $2.24 billion. The estimate points to a change of +7.6% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- World Wide Revenue- Diabetes' should arrive at $829.71 million. The estimate indicates a year-over-year change of +15.1%.
The collective assessment of analysts points to an estimated 'Net Sales- World Wide Revenue- Cardiovascular- Structural Heart & Aortic' of $993.59 million. The estimate points to a change of +6.8% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- World Wide Revenue- Medical Surgical- Surgical & Endoscopy' should come in at $1.72 billion. The estimate suggests a change of +6.8% year over year.
Analysts expect 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' to come in at $567.41 million. The estimate points to a change of +12.6% from the year-ago quarter.
Analysts predict that the 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' will reach $1.34 billion. The estimate indicates a change of +10.7% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular' reaching $714.07 million. The estimate points to a change of +11.1% from the year-ago quarter.
The consensus estimate for 'Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies' stands at $769.31 million. The estimate points to a change of +9.6% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- U.S. Revenue' will reach $4.82 billion. The estimate indicates a year-over-year change of +14.1%.
Shares of Medtronic have demonstrated returns of +5.1% over the past month compared to the Zacks S&P 500 composite's +3.7% change. With a Zacks Rank #3 (Hold), MDT is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics
The upcoming report from Medtronic (MDT - Free Report) is expected to reveal quarterly earnings of $1.39 per share, indicating an increase of 10.3% compared to the year-ago period. Analysts forecast revenues of $9.47 billion, representing an increase of 10.4% year over year.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Medtronic metrics that are routinely monitored and predicted by Wall Street analysts.
The average prediction of analysts places 'Net Sales- World Wide Revenue- Other' at $19.75 million. The estimate indicates a change of -72.6% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- World Wide Revenue- Neuroscience' will reach $2.67 billion. The estimate suggests a change of +10.7% year over year.
The combined assessment of analysts suggests that 'Net Sales- World Wide Revenue- Cardiovascular' will likely reach $3.78 billion. The estimate suggests a change of +15.2% year over year.
Analysts forecast 'Net Sales- World Wide Revenue- Medical Surgical' to reach $2.24 billion. The estimate points to a change of +7.6% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales- World Wide Revenue- Diabetes' should arrive at $829.71 million. The estimate indicates a year-over-year change of +15.1%.
The collective assessment of analysts points to an estimated 'Net Sales- World Wide Revenue- Cardiovascular- Structural Heart & Aortic' of $993.59 million. The estimate points to a change of +6.8% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- World Wide Revenue- Medical Surgical- Surgical & Endoscopy' should come in at $1.72 billion. The estimate suggests a change of +6.8% year over year.
Analysts expect 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' to come in at $567.41 million. The estimate points to a change of +12.6% from the year-ago quarter.
Analysts predict that the 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' will reach $1.34 billion. The estimate indicates a change of +10.7% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular' reaching $714.07 million. The estimate points to a change of +11.1% from the year-ago quarter.
The consensus estimate for 'Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies' stands at $769.31 million. The estimate points to a change of +9.6% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- U.S. Revenue' will reach $4.82 billion. The estimate indicates a year-over-year change of +14.1%.
View all Key Company Metrics for Medtronic here>>>Shares of Medtronic have demonstrated returns of +5.1% over the past month compared to the Zacks S&P 500 composite's +3.7% change. With a Zacks Rank #3 (Hold), MDT is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .